Halozyme Therapeutics, Inc. (HALO)
NASDAQ·Healthcare·Biotechnology
$63.70
-1.23%
Mkt Cap $8.10B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Feb 17, 2026 | $435.71M | $451.77M | +3.69% | $2.15 | -$0.24 | -111.16% | — | — |
| Q4 2025 Nov 3, 2025 | $446.51M | $354.26M | -20.66% | $1.63 | $1.72 | +5.52% | — | — |
| Q3 2025 Aug 5, 2025 | $330.78M | $325.72M | -1.53% | $1.23 | $1.54 | +25.20% | — | — |
| Q2 2025 May 6, 2025 | $280.97M | $264.86M | -5.73% | $0.95 | $1.11 | +16.84% | — | — |
| Q1 2025 Feb 18, 2025 | $285.74M | $298.01M | +4.29% | $1.17 | $1.26 | +7.69% | — | — |
| Q4 2024 Oct 31, 2024 | $292.83M | $290.08M | -0.94% | $0.98 | $1.27 | +29.59% | — | — |
| Q3 2024 Aug 6, 2024 | $208.94M | $231.35M | +10.73% | $0.76 | $0.91 | +19.74% | — | — |
| Q2 2024 May 7, 2024 | $199.78M | $195.88M | -1.95% | $0.70 | $0.79 | +12.86% | — | — |
| Q1 2024 Feb 20, 2024 | $231.14M | $230.04M | -0.48% | $0.83 | $0.82 | -1.20% | — | — |
| Q4 2023 Nov 6, 2023 | $222.63M | $216.03M | -2.96% | $0.71 | $0.75 | +5.63% | — | — |
| Q3 2023 Aug 8, 2023 | $199.95M | $221.04M | +10.55% | $0.63 | $0.74 | +17.46% | — | — |
| Q2 2023 May 9, 2023 | $175.51M | $162.14M | -7.62% | $0.48 | $0.47 | -2.08% | — | — |
| Q1 2023 Feb 21, 2023 | $192.05M | $181.50M | -5.50% | $0.47 | $0.48 | +2.13% | — | — |
| Q4 2022 Nov 8, 2022 | $191.17M | $208.98M | +9.31% | $0.52 | $0.74 | +42.31% | — | — |
| Q3 2022 Aug 9, 2022 | $138.63M | $152.37M | +9.91% | $0.50 | $0.53 | +6.00% | — | — |
| Q2 2022 May 10, 2022 | $128.25M | $117.28M | -8.56% | $0.49 | $0.47 | -4.08% | — | — |
| Q1 2022 Feb 22, 2022 | $101.54M | $102.00M | +0.46% | $0.41 | $0.42 | +2.44% | — | — |
| Q4 2021 Nov 2, 2021 | $106.96M | $115.83M | +8.29% | $0.42 | $0.55 | +30.95% | — | — |
| Q3 2021 Aug 9, 2021 | $104.04M | $136.46M | +31.16% | $0.41 | $0.62 | +51.22% | — | — |
| Q2 2021 May 10, 2021 | $83.98M | $89.02M | +6.00% | $0.31 | $0.37 | +19.35% | — | — |